UK: Biotech Services Almac Group to Scale-Up Personalized Cancer Vaccine Production
The Almac Group is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities. Doubling its footprint in the Fleming Building to over 4,500 m2, the company is investing in new laboratories and office space to meet growing demand for its services.
Edinburgh/UK — The company's Technopole site already has the world’s first GMP-certified facility specifically for the production of neo-antigenic peptide vaccines for clinical trials. Around a quarter of their existing resources in Edinburgh are currently engaged in cancer vaccine production, and the entirety of the new space will be dedicated to this application, the company announced
The expansion is to provide a four-fold increase in the GMP manufacturing footprint, as well as supporting administrative space. Having first moved to Edinburgh Technopole just a few years ago, the manufacturer had been keen to further extend their footprint on site, Alastair Hay, Account Manager Peptides, explained. The main challenge in the rapidly developing field of personalized cancer vaccines was to stay ahead of global demand, and the new laboratories — together with a commensurate growth in staff numbers — would help to achieve this, he added.